JMP Securities Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has maintained an Outperform rating on ACADIA Pharmaceuticals (ACAD) but has lowered the price target from $44 to $39.

March 12, 2024 | 10:48 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ACADIA Pharmaceuticals' Outperform rating is maintained by JMP Securities, but the price target is reduced from $44 to $39.
The reduction in the price target from $44 to $39 by JMP Securities, despite maintaining an Outperform rating, could lead to a negative short-term sentiment among investors. This adjustment reflects a revised valuation perspective, potentially due to updated analysis or market conditions affecting ACADIA Pharmaceuticals. Such a move by a reputable analyst firm might cause investors to adjust their expectations for the stock's future performance, possibly leading to a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100